Regenxbio INC Form 4 insider transactions

REGENXBIO Inc.'s CEO, Curran Simpson, sold 7,734 shares of common stock for a weighted average price of $10.02 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

REGENXBIO's Chief Technology Officer, Craig Malzahn, reported a disposition of 234 common shares for tax withholding purposes related to RSU vesting.

REGENXBIO Inc.'s Chief Financial Officer, Mitchell Chan, disposed of 4,901 common shares to cover tax liabilities related to vested restricted stock units.

REGENXBIO's Chief Strategy & Legal Officer, Patrick J. Christmas, reported a disposition of 4,699 shares of common stock to cover tax obligations related to RSU vesting.

REGENXBIO Inc.'s Chief Executive Officer, Curran Simpson, disposed of 4,701 shares of common stock valued at $8.23 per share to cover tax obligations related to the vesting of restricted stock units.

REGENXBIO Inc. Director Allan M. Fox has been granted 7,768 restricted stock units and 39,815 stock options, increasing his direct and indirect beneficial ownership in the gene therapy company.

REGENXBIO Inc. Director Jennifer Zachary was granted 7,768 restricted stock units and options to purchase 39,815 shares of common stock on May 30, 2025, as part of her compensation package.

REGENXBIO Inc. Director Daniel Tasse was granted 7,768 restricted stock units and 39,815 stock options as part of his compensation, aligning his interests with long-term company performance.

REGENXBIO Inc. Director David C. Stump was granted 7,768 restricted stock units and 39,815 stock options as part of his compensation, aligning his interests with shareholders.

REGENXBIO Inc. Director Kenneth T. Mills was granted 7,768 restricted stock units and 39,815 stock options as part of his equity compensation, aligning his interests with shareholders.

REGENXBIO Inc. Director George V. Migausky was granted 7,768 restricted stock units and 39,815 stock options as part of his compensation, aligning his interests with shareholders.

REGENXBIO Inc. Director Alexandra Glucksmann has reported the acquisition of 7,768 restricted stock units and 39,815 stock options as part of her compensation, increasing her beneficial ownership in the company.

REGENXBIO Inc. Director Argeris N. Karabelas was granted 7,768 restricted stock units and 39,815 stock options as part of his compensation, aligning his interests with the company's long-term performance.

REGENXBIO Inc. Director Jean Bennett has reported the acquisition of 7,768 restricted stock units and 39,815 stock options, reflecting new equity compensation.

Director Kenneth T. Mills exercised stock options and sold shares of Regenxbio Inc. on May 12, 2025, according to a Form 4 filing.

Patrick J. Christmas, Chief Legal Officer of REGENXBIO Inc., reports the withholding of 4,700 shares of common stock to cover taxes upon vesting of restricted stock units on February 1, 2025.

Chief Medical Officer Steve Pakola of REGENXBIO Inc. reports disposition of shares to cover tax obligations upon vesting of restricted stock units.

Olivier Danos, Chief Scientific Officer of REGENXBIO Inc., sold shares to cover tax obligations arising from the vesting of restricted stock units.

Director Kenneth T. Mills exercised stock options to acquire 30,752 shares of REGENXBIO Inc. common stock at a price of $3.76 on March 27, 2025.

REGENXBIO's CEO, Curran Simpson, received a corrected stock option grant of 478,606 shares, amending a previous filing due to a share calculation error.

Chief Medical Officer Steve Pakola reports acquisition and disposal of REGENXBIO Inc. stock and stock options.

REGENXBIO's Chief Scientific Officer, Olivier Danos, reports the withholding of shares for tax obligations and the acquisition of restricted stock units and stock options.

CEO Curran Simpson of REGENXBIO Inc. reports acquisition and disposal of company stock and stock options.

REGENXBIO's Chief Financial Officer, Mitchell Chan, was granted stock options on January 2, 2025, according to a Form 4 filing.

REGENXBIO's Chief Legal Officer, Patrick J. Christmas, reports acquiring shares through stock options and disposing of shares to cover tax obligations related to vesting restricted stock units.

Director Argeris N. Karabelas exercised stock options and sold shares of REGENXBIO Inc. on October 1, 2024, according to a Form 4 filing with the SEC.

REGENXBIO's Chief Financial Officer, Mitchell Chan, reports the acquisition of restricted stock units and stock options.

Argeris Karabelas, a director at REGENXBIO Inc., exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan on September 3, 2024.

Director Kenneth T. Mills exercised stock options to acquire 36,316 shares of REGENXBIO Inc. at a price of $0.85 per share.

Chief Medical Officer Steve Pakola of REGENXBIO Inc. reports acquiring 58,386 shares of common stock on August 1, 2024, through a restricted stock unit award.